Literature DB >> 20954588

Ocular findings in a patient with Castleman's disease before and after treatment with immunosuppression and plasmapheresis.

Rodrigo Jorge1, Ingrid U Scott, Rafael C Oliveira, Rogério A Costa, Rubens C Siqueira, Paulo Louzada-Júnior.   

Abstract

A 12-year-old girl with a 3-month history of epistaxis and Castleman's disease presented with blurred vision in both eyes for 2 weeks. Indirect ophthalmoscopy revealed a blurred optic disc margin, venous engorgement and tortuosity, intraretinal hemorrhages and cotton wool spots, and serous detachment of the neurosensory retina in the posterior pole of each eye. Fluorescein angiography and laboratory tests revealed abnormalities consistent with the clinical examination. Six months following institution of immunosuppressive treatment, cryoglobulin levels decreased and visual acuity and funduscopic abnormalities were markedly improved. However, a few microaneurysms, retinal hemorrhages, and venous engorgement and tortuosity persisted. One month after the cessation of immunosuppressive treatment, symptoms related to the hyperviscosity syndrome recurred and the patient was treated with one session of plasmapheresis. One month after the plasmapheresis, the patient's symptoms resolved, laboratory values were normal, visual acuity was 20/15 in both eyes, and the funduscopic examination of each eye was unremarkable. Copyright 2010, SLACK Incorporated.

Entities:  

Mesh:

Year:  2010        PMID: 20954588     DOI: 10.3928/15428877-20100929-10

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging        ISSN: 1542-8877


  2 in total

1.  Refractory uveitis in patient with castleman disease successfully treated with tocilizumab.

Authors:  Toshiyuki Oshitari; Fusae Kajita; Aya Tobe; Makiko Itami; Jiro Yotsukura; Takayuki Baba; Shuichi Yamamoto
Journal:  Case Rep Ophthalmol Med       Date:  2012-11-06

2.  Retinal vein occlusion during flare of multicentric Castleman's disease.

Authors:  Igor Kozak; Erin G Reid
Journal:  Clin Ophthalmol       Date:  2013-08-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.